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In our previous works we established that in an autoinflammatory condition, familial
Mediterranean fever (FMF), the gut microbial diversity is specifically restructured, which
also results in the altered profiles of microbial long chain fatty acids (LCFAs) present in
the systemic metabolome. The mainstream management of the disease is based on oral
administration of colchicine to suppress clinical signs and extend remission periods and
our aim was to determine whether this therapy normalizes the microbial LCFA profiles in
the metabolome as well. Unexpectedly, the treatment does not normalize these profiles.
Moreover, it results in the formation of new distinct microbial LCFA clusters, which are well
separated from the corresponding values in healthy controls and FMF patients without
the therapy. We hypothesize that the therapy alters the proinflammatory network specific
for the disease, with the concomitant changes in gut microbiota and the corresponding
microbial LCFAs in the metabolome.
Keywords: familial Mediterranean fever, colchicine, metabolome, gas chromatography/mass spectrometry
(GC/MS), microbial long chain fatty acids, discriminant function analysis
INTRODUCTION
The gut microbial symbionts became intimately integrated into
the normal metabolism and physiology of human beings during
the long-term co-evolutionary history of host-microbe interac-
tion (Bäckhed et al., 2005; Ley et al., 2006). The gut microbiota
evolved to play an important role in many aspects of human
health and development, including the development and proper
functioning of the immune system (Macpherson and Harris,
2004; Artis, 2008; Mazmanian et al., 2008). The optimal host-
microbiota balance that has been achieved during the extended
co-evolutionary process shaped a particular set of interactions
that is dependent on a number of environmental and genetic
factors (Spor et al., 2011).
Unlike other animals, however, the lifestyle of humans changed
dramatically due to the development of agriculture and urban
living. This cardinally changed the living conditions compared
to those of our ancestors, which now include a highly hygienic
living environment, refined, and high calorie diets, infectious
disease control through vaccination and use of antibiotics, and
many other achievements of our civilization. Due to a more pro-
tected and resourceful lifestyle and advances in medicine that
allowed controlling many infectious and hereditary diseases, the
humans also managed to escape the stabilizing pressure of natu-
ral selection. Moreover, genetics of certain complex diseases such
as Type 1 Diabetes or Rheumatoid Arthritis shows the signs of
a recent positive selection for SNPs associated with the disease
susceptibility (Corona et al., 2010).
Thus the fine-tuned host-microbiota interaction, which has
been built and refined during hundreds of millennia, in certain
cases in contemporary life may be compromised and result in
severe disease. A very good example of this dysfunctional inter-
action between the host and commensal microbiota is inflamma-
tory bowel disease (IBD), which involves both the environmental
and genetic components (Sartor, 2006; Van Limbergen et al.,
2007). Besides the clinical manifestations, a broader picture of
the disease includes a heavily biased structure of gut microbiota
(Manichanh et al., 2006; Frank et al., 2007; Qin et al., 2010).
In our previous works we focused on host-microbiota inter-
action in an autoinflammatory disease, familial Mediterranean
fever (FMF, MIM249100) (Khachatryan et al., 2008; Manukyan
et al., 2008b; Ktsoyan et al., 2010). This disease is the most com-
mon member of hereditary autoinflammatory diseases and it is
characterized by recurrent self-resolving acute attacks of fever
and polyserositis. Mutations responsible for the disease onset and
periodic inflammation are located in theMEFV gene (The French
FMF Consortium, 1997; The International FMF Consortium,
1997), which encodes the protein called pyrin ormarenostrin, one
of the regulators of innate immunity.
The mutations in the gene are ancient and the estimated
ages for the most recent common ancestor for the frequently
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encountered mutations such as M694V, M694I, V726A, M680I,
and E148Q are 7000, 8500, 15,000, 23,000, and 30,000 years,
respectively (Jalkh et al., 2008). Jews are the most proba-
ble founder population for several common MEFV mutations
(Papadopoulos et al., 2008). This ismost likely due to early genetic
isolation and small population sizes at times (bottleneck effect),
the prerequisites for intensive genetic drift and mutation fixation.
The mutations, however, penetrated into other populations orig-
inating from the Mediterranean basin (Armenians, Arabs, and
Turks) and the carrier frequency in these populations is very
high (Aksentijevich et al., 1999). These frequencies cannot be
explained solely by intense inbreeding and increased genetic drift
though. Moreover, the presence of recurrent mutations inMEFV,
with the reappearance of an ancestral amino acid state, implies
a strong positive selection (Schaner et al., 2001). Interestingly,
amino acid substitutions that cause human disease are often
present as wild type in other species of primates suggesting that
the effect of mutations is dependent on the environmental/genetic
context. Still, it remains an open question, what kind of selective
advantage had been conferred by these MEFV alleles to the pre-
historic human populations as well as to the primates in the wild
nowadays. In the contemporary living environment of humans,
the mutation effects are debilitating and result in the increased
morbidity and mortality if left untreated.
Clinically, the disease is characterized by acute self-resolving
attacks of fever with serositis such as peritonitis, pleuritis, and
arthritis, with a massive influx of polymorphonuclear leuko-
cytes into the affected tissues. In remission the patients are
clinically asymptomatic although a number of inflammation
markers are elevated suggesting a persisting subclinical inflam-
mation (Manukyan et al., 2008a). Factors contributing to the
recurrent disease attacks remain elusive and thought to be due
to emotional, physiological, or physical stress, change of diet,
menstrual periods, and other, less defined factors (Sohar et al.,
1967; Schwabe and Peters, 1974). In a recent study employing
the case-crossover design, the authors found a positive, statisti-
cally significant relation between the number of stressful events
and FMF attacks (Yenokyan and Armenian, 2012). The results of
this epidemiological study are consistent with the earlier inter-
vention studies that induced FMF-resembling attacks in FMF
patients, but not in control subjects, by infusion of metaraminol,
a potent sympathomimetic amine used in the prevention and
treatment of hypotension (Barakat et al., 1984). It is not an
improper sympatho-adrenal response to stress though because
the responses to metaraminol as well as to stressful conditions in
the form of attacks are delayed (Barakat et al., 1984; Yenokyan
and Armenian, 2012). Most likely, the catecholamines induce
the secondary effect such as the increased exposure to gut bac-
terial products due to the decreased gut motility. Interestingly,
the metaraminol-induced attacks can be prevented with pro-
phylactic colchicine therapy (Barakat et al., 1984), which serves
as another evidence to rule out the direct involvement of the
hypothalamic-pituitary-adrenal axis response in disease attacks.
The mainstream management of the disease is based on the
daily per os administration of colchicine, which has a proven
record of prevention of attacks and amyloid deposition in FMF
(Kallinich et al., 2007). This antimitotic drug helps to reduce the
frequency, duration and intensity of disease relapses and extend
the remission periods. It is effective in prevention of FMF com-
plications such as amyloidosis and renal failure too (Niel and
Scherrmann, 2006). Colchicine is also used for the management
of Behcet’s disease, gout and cirrhosis and it is difficult to propose
the unifying mechanistic explanation for the positive effect of this
drug on the diseases with such different etiologies (Ben-Chetrit
et al., 2006).
Previously, we showed that this autoinflammatory condition
results in cardinal restructuring of gut microbiota (Khachatryan
et al., 2008), accompanied by changes in microbial products cir-
culating in the systemic metabolome (Ktsoyan et al., 2010). We
also demonstrated the increased systemic reactivity against the
commensal gut microbiota in FMF, thus suggesting a possible
mechanism for restructuring the gut microbiota composition in
an autoinflammatory condition (Manukyan et al., 2008b). In the
present work our main aim was to investigate if the colchicine
therapy, which is used to suppress the disease manifestations and
extend remission periods, is also “normalizing” the metabolome
composition, in particular its microbial compound concentra-
tions and profiles.
MATERIALS ANDMETHODS
SUBJECTS
A total of 34 FMF patients (11 females and 23 males, aged from
15 to 54 years) and 43 healthy subjects (23 females and 20 males,
aged from 25 to 42 years) were enrolled in this study. In the FMF
group, the cohorts comprised of: patients in attack period (1)
without colchicine treatment (n = 9) and (2) colchicine-treated
(n = 13); patients in remission period (3) without colchicine
treatment (n = 5) and (4) colchicine-treated (n = 7). All cases
of FMF were diagnosed based on Tel-Hashomer criteria (Livneh
et al., 1997) with further genetic confirmation for the carriage
of the MEFV mutations. Colchicine for management of FMF
was administered orally at the daily dose of 0.5–1.0mg and the
drug was taken for at least a year. Patients that administered the
drug only during attack periods were excluded from the analy-
sis. The control group comprised of healthy volunteers without
any family history of FMF; they were also checked for the MEFV
mutations. They did not suffer from any disease during the sam-
pling period. None of the FMF patients and healthy individuals
had used antibiotics within at least 3 months prior to sampling.
All study participants gave their informed consent to the protocol,
which was approved by the local ethical committee of the Institute
of Molecular Biology, NAS RA.
SAMPLE PREPARATION
Venous blood samples for gas chromatography/mass spectrome-
try (GC/MS) analysis were collected into sterile heparinized vials
and immediately frozen at −20◦C until analysis. Defrosted blood
samples (50μl) were air dried at 80◦C and subjected to acid
methanolysis using 0.4ml of 1MHCl in methanol for 1 h at 80◦C.
As a result, fatty acids and aldehydes were extracted from the com-
plex microbial lipids in the form of methyl esters and aldehyde
dimethyl acetals. Internal standard, deuteromethyl ether of tride-
cane acid, prepared in hexane, was added to the cooled reaction
mixtures at 300 ng. The fraction of methyl esters of fatty acids
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with other lipid components was extracted twice from the reac-
tion mixture with 200μl of hexane. The hexane extracts were
dried at 40◦C, and the dry residue was treated with 20μl of
N,O-bis-(trimethylsilyl)trifluoroacetamide for 15min at 80◦C to
form trimethylsilyl derivatives of hydroxy acids (Beloborodova
and Osipov, 2000).
GC/MS ANALYSIS
A GC/MS system (Agilent AT-5973, Agilent Technologies) with
a cross-linked methyl silicone capillary column (DB-5ms EVDX;
dimensions: 0.2mm × 25m × 0.33mkm, Agilent Technologies)
was used to identify microbial components and metabolites in
blood. Two microliters of a sample derived as described in the
previous section was injected into the capillary column. Fatty
acids and other lipid components, separated in the GC column,
were analyzed in the selected ion-monitoring (SIM)mode (multi-
ion mass-fragmentography regimen). The substances eluted were
identified by measuring the specific retention times and the ratio
of chromatographic peak areas for selected ions were measured
primarily in the automatic mode by using the standard library
search program (NIST 02 MS library), with a subsequent man-
ual check of peaks. Correlation between the products identified
and the corresponding source microorganisms was carried out as
described before (Osipov and Turova, 1997; Osipov et al., 2009)
using the Sherlock® Microbial 2 Identification System (MIS)
(www.midi-inc.com).
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS package (SPSS
Inc., Chicago, IL, USA). The Mann–Whitney U-test was applied
to determine statistical significance among the mean values of
studied groups. P-values below 0.05 were considered as statisti-
cally significant. Discriminant function analysis (DA) was used
to classify cases into groups. The investigated groups of subjects
were taken as dependent variables of DA and concentrations of
microbial components in the blood were taken as predictors.
RESULTS
Wedetermined the concentrations of systemic hydroxy, branched,
cyclopropyl, and unsaturated fatty acids as well as aldehydes
among the FMF and control cohorts. The results are presented
in the form of median and interquartile range (25th and 75th
percentiles) for all five cohorts studied (Table 1). Statistical sig-
nificance of pairwise differences among the groups is also shown.
Interestingly, concentrations of systemic microbial mark-
ers were similar between the colchicine-treated and untreated
patients in remission, we found no statistically significant differ-
ences between them. At the same time, in the attack period, a
statistically significant two-fold increase in the level of certain sys-
temic microbial markers was found among the colchicine-treated
patients compared to the untreated group. These long chain fatty
acids (LCFAs) were: iC18:0 (marker present in Peptostreptococcus,
Clostridium difficile, and Bifidobacterium), C17cyc (present in
Enterobacteriaceae, Pseudomonas, and Alcaligenes), and C19cyc
(present in Lactobacillus and Enterococcus).
In general, statistically significant pairwise differences in con-
centration of microbial markers were not associated with the use
of colchicine, but rather with the health status or the disease stage
(Table 1). In particular, the corresponding values were signifi-
cantly different among the group of colchicine-treated patients in
attack period and both groups of patients in remission compared
to control. For example, significantly higher levels of systemic
hydroxy FAs were revealed in colchicine-treated patients in attack
compared to the normal subjects (with the exception of 3hC12:0).
Even higher levels of almost all hydroxy FAs were uncovered in
the remission stage (irrespectively of colchicine intake) compared
to control (Table 1). It is noteworthy that 2hC12:0 and 3hC12:0
are the signature compounds of non-fermentative Gram-negative
bacteria (NFB), while 3hC18:0 and 10hC18:0 are the refer-
ence markers for Helicobacter pylori, and Clostridium perfringens,
respectively.
Interestingly, the concentrations of systemic hydroxy FAs such
as i18, 17cyc, and 19cyc, but with the exception of 3hC12:0, were
similar between the patients in attack without colchicine treat-
ment and the normal subjects. Surprisingly, colchicine treatment
in this group leads to the elevation of these microbial markers up
to two- and four-fold compared to control (Table 1).
On the contrary, the concentration of another group of sys-
temic microbial components, unsaturated FAs, was significantly
different between the patients in attack period without colchicine
treatment and controls (Table 1). In particular, the concentra-
tions of C14:1d9, C14:1d11, C15:1d, C16:1d7, and C16:1d11
were significantly decreased in these patients compared to con-
trols. These microbial components are relevant to Clostridium,
Nocardia, Clostridium propionicum, Bacteroides hypermegas,
Ruminococcus, Clostridium ramosum, and Clostridium innocuum
(Table 1). The effect of colchicine treatment in these patients was
limited and led to the reduction of only C14:1d11 and C16:1d7
compared to the healthy subjects. It should be noted that there
were no statistically significant differences in the level of unsat-
urated FAs in the remission period vs. control, regardless of
colchicine treatment.
Without the colchicine therapy, concentrations of FAs such
as iC18:0, C17cyc and C19cyc in the metabolome of patients in
remission were almost four-fold higher compared to the control
and attack-period subjects (Table 1). In the case of the colchicine
therapy, the concentration of these metabolites was very similar,
irrespective of the disease stage, and were elevated only twice vs.
control and patients in attack without colchicine treatment. The
same tendency, but to a lesser extent, was observed for C17:1d9,
one of the biomarkers of Candida albicans.
As for the disease stage, comparative analyses of micro-
bial components in the systemic metabolomes of FMF patients
during attack and remission periods revealed that these two
groups are substantially more different without the treatment
by colchicine, while the corresponding therapeutic intervention
negates these differences (Table 1). In particular, in the absence
of the colchicine therapy, the systemic concentrations of 3hC18:0,
10hC18:0, C17cyc, C19cyc, C14:1d11, C16:1d17, C16:1d11, and
C17:1d9 were significantly reduced in the attack period compared
to remission, while under the therapy these concentrations were
very similar, with the exception of C14:1d11 (Table 1).
The negating effect of the colchicine therapy on the
metabolome profile was not consistent through the range of
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Table 1 | Concentration of microbial compounds and the potential source in blood of FMF patients and healthy controls.
Substance Potential microbial
sourcea
Healthy controls
(n = 43)
FMF attack FMF remission
Colchicine − d
(n = 9)
Colchicine +e
(n = 13)
Colchicine − d
(n = 5)
Colchicine +e
(n = 7)
HYDROXY FATTY ACIDS (FA)
2-hydroxy lauric (2 hC12:0)b Pseudomonas
aeruginosa,
Acinetobacter
0.90 (0.70–1.10)c 0.8 (0.6–1.6) 1.4 (1.1–1.9)* 1.5 (1.5–3.9)* 2.4 (1.75–3.90)*#
3-hydroxy lauric (3 hC12:0) Pseudomonas,
Moraxella,
Acinetobacter
2.70 (2.00–3.65) 1.5 (1.1–2.8) 2.8 (1.6–3.5)† 4.2 (4.0–4.2)# 5.60 (5.00–6.15)*#
3-hydroxy stearic (3 hC18:0) Helicobacter pylori 11.3 (9.2–16.0) 10.9 (9.9–12.8) 18.5 (10.8–44.0)* 40.9 (21.8–56.1)*# 20.1 (19.0–46.4)*#
10-hydroxy stearic (10 hC18:0) Clostridium perfringens 27.4 (16.7–36.5) 28.8 (20.4–33.1) 43.4 (27.1–57.5)* 64.8 (54.9–67.8)*# 43.9 (35.4–95.7)*#
BRANCHED FA
iso-myristic (iC14:0) Peptostreptococcus,
Streptomyces, Bacillus,
Bacteroides,
79.8 (50.7–108.8) 49.4 (40.9–119.6) 61.9 (44.2–84.7) 54.9 (30.0–100.5) 81.7 (64.7–114.8)
iso-pentadecanoic (iC15:0) Propionibacterium,
Bacteroides,
Staphylococcus
366 (292–621) 272 (184–568) 454 (264–508) 429 (195–480) 439 (289–639)
iso-palmitic (iC16:0) Streptomyces,
Bacteroides,
Micromonospora
1193 (862–1563) 996 (817–1669) 1167 (902–1342) 1238 (755–1330) 1425 (1074–1823)
iso-heptadecanoic (iC17:0) Bacillus, Prevotella,
Propionibacterium,
Staphylococcus
2794 (1824–3921) 2381 (1924–3354) 2737 (2120–3709) 2660 (1944–2902) 3749 (2880–4092)
iso-stearic (iC18:0) Peptostreptococcus,
Clostridium difficile,
Bifidobacterium
26.7 (16.75–36.5) 26.9 (20.6–31.0) 56 (41–130)*# 106 (52–113)*# 52.4 (42.9–77.0)*#
anteiso-pentadecanoic
(aC15:0)
Staphylococcus,
Bacillus,
Corinebacterium
377 (316–607) 307 (236–622) 325 (285–558) 411 (190– 469) 558 (367–822)
anteiso-heptadecanoic
(aC17:0)
Corinebacterium,
Bacteroides,
Micromonospora,
Staphylococcus
1601 (1215–2232) 1519 (967–2259) 1657 (1258–2068) 1879 (1105–1918) 2075 (1583–2589)
anteiso-nonadecanoic
(aC19:0)
Staphylococcus 179 (136–213) 181 (139–236) 176 (160–206) 206 (158–212) 205 (196–269)
CYCLOPROPYL FA
Cyclopropylheptadecanoic
(C17cyc)
Enterobacteriaceae,
Pseudomonas,
Alcaligenes
1.60 (1.05–2.25) 1.8 (1.4–2.7) 3.4 (2.0–9.1)*# 5.6 (5.3–6.3)*# 4.20 (3.40–5.45)*#
Cyclopropylnonadecanoic
(C19cyc)
Lactobacillus,
Enterococcus
19.9 (13.05–32.7) 22.3 (18.5–23.1) 39.5 (25.3–136.2)*# 93.3 (45.2–112.4)*# 46.3 (37.5–56.4)*#
UNSATURATED FA
cis-9-tetradecenoic (C14:1d9) Clostridium 20.0 (7.5–28.8) 6.2 (5.2–11.5)* 12.2 (7.3–18.7) 11.2 (7.8–28.1) 29.6 (13.6–34.9)#
cis-11-tetradecenoic
(C14:1d11)
Nocardia 142 (78–364) 67.8 (45.6–123.6)* 79 (61–127)* 167 (141–228)# 169 (97–186)
cis-9-pentadecenoic
(C15:1d9)
Clostridium
propionicum,
Bacteroides
hypermegas
8.30 (5.00–15.15) 4.5 (3.7–6.6)* 6.5 (5.3–11.7) 6.8 (5.6–8.0) 9.1 (7.7–23.8)#
cis-7-hexadecenoic (C16:1d7) Clostridium ramosum,
C. innocuum,
C. clostridioforme
1054 (859–1290) 760 (623–877)* 847 (597–978)* 1058 (974–1195)# 846 (710–1019)
cis-11-hexadecenoic
(C16:1d11)
Ruminococcus,
Nocardia,
Fusobacterium
157 (110–236) 89 (69–129)* 133 (101–169) 164 (139–189)# 193 (135–225)
cis-9-heptadecenoic
(C17:1d9)
Candida albicans 210 (149–301) 248 (181–292) 421 (222–697)* 564 (414–589)*# 364 (271– 634)*
cis-11-octadecenoic
(C18:1d11)
Bacteroides,
Fusobacterium,
Enterobacteriaceae,
Pseudomonas,
Lactobacillus
4594 (2655–5915) 3826 (3643–5929) 4533 (3283–5030) 5131 (4372–6121) 4060 (3743–4956)
cis-9-eicosenoic (C20:1d9) Propionibacterium
jensenii, Actinomyces
840 (725–954) 732 (631–846) 779 (665–841)† 855 (846–1044)* 973 (916–1044)*#
(Continued)
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Table 1 | Continued
Substance Potential microbial
sourcea
Healthy controls
(n = 43)
FMF attack FMF remission
Colchicine − d
(n = 9)
Colchicine +e
(n = 13)
Colchicine − d
(n = 5)
Colchicine +e
(n = 7)
cis-11-eicosenoic
(C20:1d11)
P. jensenii,
Actinomyces,
Streptococcus
72.2 (54.6–100.9) 64.2 (59.0–98.2) 61.3 (50.8–76.7)† 101 (60–116) 81.4 (78.8–93.4)
ALDEHYDES
cis-vaccinic
(C18:1d11A)
Eubacterium
moniliforme, S.
mutans, C. ramosum
4072 (3260–5252) 2809 (2067–5621) 3353 (3027–4578) 3631 (2101–4475) 3219 (2634–3289)*
Oleic (C18:1d9A) Bifidobacterium
bifidum,
Propionibacterium
11518 (9277–13406) 11276 (8353–11640) 9469 (8788–12420) 9166 (8597–9278) 9110 (8020–10059)*
Anteisoheptadecanoic
(aC17A)
Eubacterium lentum,
Propionibacterium
acnes
1014 (688–1474) 1279 (1097–1768) 1316 (988–1927)*† 788 (779–941) 789 (645–845)
iso-palmitic (iC16A) E. lentum 386 (278–538) 511 (348–613) 465 (372–576) 352 (299–372) 355 (263–365)
Anteisopentadecanoic
(aC15A)
Eubacterium,
Peptostreptococcus
119 (75–184) 86.8 (56.6–142.8) 111.6 (90.5–151.4) 152 (83–182) 102 (95–148)
Myristic (C14A) E. lentum, B. bifidum 85.3 (61.3–134.0) 99.5 (59.4–107.3) 96.4 (85.1–122.7) 88.3 (73.5–102.0) 136 (85–152)
iso-myristic (iC14A) 92.6 (57.4–131.3) 118 (81–151) 109 (93–119)† 66.6 (65.2–67.8) 71.1 (61.4–77.9)
a The majority of bacteria belongs to the four phyla found in the human gut (Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria).
b Codes of chemical substances are given in parenthesis.
c Median values (ng/ml) followed by the interquartile range in parenthesis (25th and 75th percentiles).
d FMF patients without colchicine treatment.
e FMF patients on colchicine therapy.
Statistical significance of intergroup differences according to the Mann–Whitney U-test.
*p < 0.05 significance compared to healthy controls.
#p < 0.05 significance compared to the group of FMF patients in attack period without colchicine treatment.
†p < 0.05 significance compared to the group of colchicine-treated FMF patients in remission period.
all metabolites though. It may also contribute to the appear-
ance of significant differences in the systemic microbial LCFAs
between the attack and remission periods. This was noted for
the following substances: C20:1d9 and C20:1d11 (biomarkers
of Propionibacterium jensenii, Actinomyces, and Streptococcus),
a17a (Eubacterium lentum and Propionibacterium acnes) and i14a
(Table 1). The direction of the concentration change is also not
consistent: the latter two aldehydes were elevated in the attack
compared to remission period, while the others demonstrated the
opposite trend.
The only component of the metabolome that was significantly
elevated in remission vs. attack period, regardless of the colchicine
therapy, was 3hC12:0 (biomarker of NFB) (Table 1). It was also
significantly elevated compared to the healthy subjects.
The results of the pairwise analyses do suggest that there
are substantial differences in the metabolome due to the health
status, stage of disease, and the colchicine therapy. Due to the
complexity of these effects, further analyses included multivari-
ate statistics, in particular, DA, to verify if the concentration of
microbial products in the systemic metabolome may discriminate
among the groups and serve as a predictor of a group mem-
bership. To test this approach, the raw data were subjected to
DA, using 30 microbial products in the metabolome as predic-
tors (Figure 1). According to this analysis, the variables accurately
discriminated the groups and form five separate clusters cor-
responding to the cohorts under investigation. Moreover, the
predicted group membership was also fairly accurate, with 90.9%
of original grouped cases correctly classified (Table 2). The statis-
tical significance of the DA model was also well supported by the
Wilks’s lambda test, with the corresponding coefficient value of
0.026 (Table 3).
The DA analysis showed distinct clustering of both groups of
patients in remission from other cohorts studied with 100% accu-
racy (Table 2). It should be noted that in the remission period
separation of patients subjected or not subjected to colchicine
treatment was observed with 100% accuracy, despite the fact that,
as it was mentioned above, there were no statistically significant
pairwise differences between the colchicine-treated and untreated
patients at this stage of the disease. This demonstrates that the
variables, i.e., the concentrations of microbial components in the
metabolome, are highly cohort-specific.
Since colchicine is the main drug used to manage this dis-
ease, it was expected that the profiles of microbial products in
patients under the therapy would be “normalized,” following the
suppression of clinical manifestations of the disease. However, the
effect of colchicine was quite the opposite, forming new distinct
profiles of microbial products in the metabolome, well sepa-
rated from the healthy controls and FMF patients without the
therapy.
DISCUSSION
Previously, we have established that FMF results in a spe-
cific restructuring of gut microbiota affecting the major phyla
present (Khachatryan et al., 2008). Correspondingly, the profile
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FIGURE 1 | Scatterplot of DA model based on systemic concentration of
microbial components of the metabolome. Number of variables in the
model—30 and grouping consists of five groups. Root 1, 2—discriminant
functions 1 and 2 (1st and 2nd canonical roots). , Healthy subjects; , FMF
patients in attack period without colchicine treatment; , FMF patients in
attack period under colchicine treatment; , FMF patients in remission period
without colchicine treatment; , FMF patients in remission period under
colchicine treatment; , group centroid.
Table 2 | Predicted group membership based on 30 variables.
Groups Predicted group membershipa Total
1 2 3 4 5
Count 1 40 3 0 0 0 43
2 1 7 1 0 0 9
3 1 1 11 0 0 13
4 0 0 0 5 0 5
5 0 0 0 0 7 7
% 1 93.0 7.0 0.0 0.0 0.0 100.0
2 11.1 77.8 11.1 0.0 0.0 100.0
3 7.7 7.7 84.6 0.0 0.0 100.0
4 0.0 0.0 0.0 100.0 0.0 100.0
5 0.0 0.0 0.0 0.0 100.0 100.0
a90.9% of original grouped cases are correctly classified.
of microbial LCFAs circulating in the blood is also specific for
the diseased and healthy states (Ktsoyan et al., 2010). In this
work, we addressed the question whether the colchicine ther-
apy that is used to suppress the clinical manifestations of FMF
and to extend the remission periods could also have an effect
on the level and profile of microbial LCFAs in systemic circula-
tion. Surprisingly, the suppression of clinical signs of the disease
by the therapy does not result in the normalization of microbial
LCFAs in the metabolome. On the contrary, the treatment results
in the formation of new distinct microbial LCFA profiles in the
Table 3 | Wilks’s lambda test.
Test of function(s) Wilks’ lambda Chi-square Df Sig.
1–4 0.026 213,837 120 0.000
2–4 0.109 129,794 87 0.002
3–4 0.359 60,007 56 0.333
4 0.656 24,677 27 0.593
metabolome, which are well separated from the corresponding
profiles of healthy controls and FMF patients without the therapy
(Figure 1).
The effect of colchicine on gut microbiota can be exerted
in two possible ways: (1) direct influence of this peroral drug
on gut microbiota and (2) indirect influence through the host
responses to the therapy. There are very few literature sources
concerning the direct effect of colchicine toward microorgan-
isms. The antimicrobial effect of colchicine was tested in vitro
against a number of potential pathogens and the MICs obtained
were well within the concentration range of the most com-
mon antibiotics used (Ozçelik et al., 2011). However, the ther-
apeutic dosage of antibiotics prescribed is much higher, more
than by the two orders of magnitude, than the usual thera-
peutic concentrations of colchicine. It is highly unlikely there-
fore, that colchicine may exert any antimicrobial activity at
the concentrations used for FMF therapy and contribute to
the observed shifts of microbial LCFAs in systemic circulation.
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In the latter scenario, colchicine may interfere with the for-
mation of microtubules (Massarotti et al., 2012), thereby affect-
ing mitosis and other microtubule-dependent functions such as
diapedesis. As a consequence of the reduced mobility, the infil-
tration of leukocytes into the affected sites may be impeded,
thus reducing the subclinical inflammation in the gut (Niel and
Scherrmann, 2006). The restoration of the compromised gut
epithelial barrier due to the colchicine therapy may result in a
lower frequency of microbial translocation in the gut. Indeed,
when assessing the influence of colchicine treatment on systemic
immunoglobulin isotypes in FMF patients, we found the “nor-
malizing” effect of the therapy on the level of systemic IgAs that
were directed toward the protein antigens of commensal gut bac-
teria (Manukyan et al., 2008b). The concentration of microbial
LCFAs in the metabolome, however, is less responsive to the
colchicine intake and, for example, there are no statistically sig-
nificant differences between the colchicine-treated and untreated
patients in the remission period. Moreover, in disease attacks,
the level of certain microbial LCFAs such as iC18:0, C17cyc and
C19cyc is actually significantly higher in the colchicine-treated
cohort compared to the untreated (Table 1). This is surprising
since the total number of fecal bacteria falls substantially dur-
ing the attack periods (Khachatryan et al., 2008) and suggests the
overgrowth of certain groups of bacteria with these specific LCFA
signatures due to the colchicine treatment.
Despite the absence of pairwise statistically significant differ-
ences between the colchicine-treated and untreated cohorts in
the remission period (Table 1), these groups are clearly sepa-
rated when the multivariate statistics analysis tools are applied
(Figure 1). The concentration of 30 microbial LCFAs in the
metabolome used as variables in the DA model allows predicting
the disease stage and the impact of the therapeutic intervention
with a 100% accuracy (Table 2). Although the vast majority of
microbial markers in the attack period are also not responsive
to the treatment (Table 1), the two groups form distinct clusters
in the DA model (Figure 1), albeit with a less predictive mem-
bership accuracy compared to the remission groups (Table 2).
These results suggest that the colchicine therapy, which suppresses
the clinical signs of the disease and extend the asymptomatic
remission periods, does not “normalize” the gut microbiota com-
position as judged by the profiles of microbial LCFAs in the
metabolome. Moreover, the therapy actually shifts the composi-
tion toward a new equilibrium, which is different from the healthy
and untreated disease states. This new equilibrium is certainly
mediated by the host, which responses are modified by the drug
action.
The colchicine therapy restricts the infiltration of neutrophils
to the affected sites due to the interference with the microtubule-
dependent functions such as diapedesis (Massarotti et al., 2012).
Another effect of colchicine is realized at the transcription regu-
lation level and includes inflammation and interferon-associated
genes (Ben-Chetrit et al., 2006). We hypothesize that as a con-
sequence of the limited neutrophils infiltration and differen-
tial expression of inflammation and interferon-associated genes
during the colchicine treatment, the balance of pro- and anti-
inflammatory mediators is shifted, similarly to the shifts in
cytokine profile that are disease-specific (Manukyan et al., 2010).
This may result in differential immune responses in colchicine-
treated and untreated FMF patients. Indeed, in our preliminary
work, we found the increased phagocytic activity of neutrophils
in the blood of colchicine-free FMF patients compared to the
treated at the stage of remission and healthy controls, up to
two- and four-fold, respectively (unpublished data). Moreover,
it appears to be that colchicine, in addition to its well-known
anti-inflammatory activity, may actually exert a potent pro-
inflammatory activity up-regulating, in particular, the expres-
sion of IL-1β and IL-8 mRNAs (unpublished data). As a result
of the restructured inflammatory environment in the gut, the
microbiota composition is also altered with the concomitant
alteration in the concentration of microbial LCFAs entering into
the systemic circulation. Further investigations are needed to
validate this hypothesis regarding the effects of colchicine ther-
apy in FMF, with larger cohorts and parallel microbial diversity
analyses.
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